BSE Live
Mar 13, 16:01Prev. Close
1559.55
Open Price
1560.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 13, 15:56Prev. Close
1560.80
Open Price
1567.00
Bid Price (Qty.)
1561.30 (62)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Ipca Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 738.89 | 546.46 | 290.53 | 262.06 | 116.64 | |
| Net CashFlow From Operating Activities | 564.27 | 501.03 | 341.13 | 281.91 | 708.65 | |
| Net Cash Used In Investing Activities | -509.65 | -165.06 | -135.40 | -148.82 | -218.33 | |
| Net Cash Used From Financing Activities | -130.46 | -183.20 | -130.41 | -159.13 | -461.51 | |
| Foreign Exchange Gains / Losses | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -75.53 | 152.77 | 75.32 | -26.04 | 28.81 | |
| Cash And Cash Equivalents Begin of Year | 370.92 | 218.15 | 142.83 | 168.87 | 140.06 | |
| Cash And Cash Equivalents End Of Year | 295.39 | 370.92 | 218.15 | 142.83 | 168.87 |
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
18.02.2026
Buy Ipca Laboratories; target of Rs 1710: Prabhudas Lilladher
17.02.2026
09.02.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
13.03.2026
13.03.2026
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth